Characterise pathological sleepiness, recognise narcolepsy and cataplexy, arrange valid specialist testing, and manage driving, occupational and prescribing risks while considering common alternative causes.
Excessive daytime sleepiness means difficulty maintaining wakefulness with unintended sleep, not simply feeling drained. Ask where sleep occurs, whether it is irresistible, how refreshing naps are, and whether there have been driving or occupational incidents. Quantify habitual sleep opportunity across work and free days. Chronic sleep restriction is common and must be corrected before interpreting a central hypersomnolence test.
Narcolepsy type 1 is associated with orexin deficiency and cataplexy or low cerebrospinal-fluid hypocretin in an appropriate syndrome. Type 2 has narcolepsy physiology without cataplexy or documented hypocretin deficiency. Cataplexy is usually triggered by laughter, surprise or anger, lasts seconds to minutes and preserves awareness. Sleep paralysis and vivid sleep-transition hallucinations are supportive but also occur in the general population and with sleep deprivation.
The differential includes insufficient sleep, obstructive sleep apnoea, circadian misalignment, shift work, sedating medicines, alcohol or drugs, depression, hypothyroidism, anaemia, restless legs and other neurological disorders. Idiopathic hypersomnia can cause persistent sleepiness, long unrefreshing sleep and marked sleep inertia. A targeted medical assessment is preferable to indiscriminate laboratory panels.
Narcolepsy type 1 usually reflects loss of hypothalamic orexin-producing neurons, with genetic susceptibility and probable immune-mediated mechanisms.
Sleep restriction, apnoea, circadian misalignment, medicines, substances, mood disorder and neurological disease commonly cause or worsen daytime sleepiness.
Reduced orexin signalling weakens stable wakefulness, allowing rapid transitions into sleep despite attempts to remain alert.
REM phenomena cross into wake transitions, producing cataplexy, paralysis and vivid hallucinations alongside sleep-onset REM periods.
Narcolepsy destabilises both day and night, causing daytime sleep intrusion alongside repeated nocturnal waking rather than simple excess total sleep.
Unintended sleep intrudes into conversation, travel or activity despite attempted wakefulness and adequate opportunity for night sleep.
Brief emotion-triggered bilateral loss of muscle tone occurs with retained consciousness, ranging from facial slackening to collapse.
Sleep paralysis and vivid hallucinations at sleep onset or awakening reflect REM features crossing state boundaries but are not individually diagnostic.
Narcolepsy can produce repeated night waking despite rapid sleep onset, so daytime sleepiness does not always imply uninterrupted long sleep.
Prolonged severe difficulty waking and unrefreshing long sleep suggests idiopathic hypersomnia or accumulated deprivation rather than classic refreshing narcoleptic naps.
Habitual sleep opportunity is shorter than biological need, with improvement when sufficient sleep is consistently permitted and documented.
Snoring, witnessed breathing pauses and fragmented sleep produce sleepiness and require respiratory evaluation before central hypersomnolence attribution.
Persistent sleepiness, long unrefreshing sleep and severe sleep inertia occur without cataplexy or the typical narcoleptic REM pattern.
Loss of consciousness, stereotyped motor activity, cardiovascular prodrome or post-event confusion distinguishes episodic collapse from cataplexy.
Unintended sleep and cataplexy can cause driving, workplace, cooking and fall-related injuries without timely restriction and treatment.
Sleep episodes, cognitive impairment and stigma may be misread as laziness, reducing attainment, employment and social participation.
Wake-promoting drugs can produce cardiovascular, psychiatric, dermatological, reproductive and interaction harms that require structured specialist monitoring.
The person can usually hear and remember during brief emotion-triggered weakness; loss of consciousness or prolonged focal deficit needs another explanation.
Insufficient sleep, shift work, circadian delay and REM-suppressing or stimulating medicines can distort latency and REM-onset results, so protocol quality matters.
The associated HLA type is common in people without narcolepsy and therefore does not replace clinical phenotype and specialist physiological testing.
Brief naps are often refreshing in narcolepsy, whereas idiopathic hypersomnia may involve long unrefreshing sleep and pronounced difficulty waking.
The legal and safety response begins when excessive sleepiness affects driving, before formal sleep-service diagnosis and before a treatment trial is completed.
Using fatigue and sleepiness interchangeably, which obscures both central hypersomnolence and non-sleep causes of exhaustion.
Ordering MSLT after restricted sleep, shift work or unplanned medicine changes and treating the result as self-validating.
Diagnosing narcolepsy from isolated sleep paralysis or hallucinations, which also occur with sleep deprivation and in healthy people.
Calling every collapse cataplexy without establishing an emotional trigger, preserved awareness and brief bilateral tone loss.
Prescribing modafinil without explicit pregnancy, contraception, interaction, rash, psychiatric and cardiovascular counselling.
Telling a patient to resume driving once medication helps rather than following DVLA notification and licensing requirements.
Your practice draft is saved in this browser.
A woman with irresistible daytime sleep episodes develops brief knee buckling and jaw slackening whenever she laughs, remains fully aware and recovers within seconds. Which feature most strongly points to cataplexy?
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem ·
Specialist diagnosis usually uses an overnight polysomnogram to assess sleep duration and exclude another sleep disorder, followed the next day by multiple sleep latency testing under controlled conditions. A short mean latency and sleep-onset REM periods support narcolepsy in the correct context. HLA typing lacks sufficient specificity for routine confirmation. CSF hypocretin is a specialist test in selected cases, particularly when cataplexy is typical but standard testing is inconclusive or impractical.
Management addresses safety first. Regular sleep, planned short naps and adjustments at work or education complement medication. Modafinil is an established wake-promoting option for adult narcolepsy; pregnancy prevention and interactions need explicit counselling. NICE recommends solriamfetol within a narrower pathway after modafinil and either dexamfetamine or methylphenidate are ineffective or unsuitable. Treatment response includes driving-level alertness, but patients follow DVLA decisions rather than self-certifying control.
Contraindicated in uncontrolled moderate-to-severe hypertension and cardiac arrhythmias. Obtain an ECG before treatment and monitor blood pressure and heart rate; discontinue at the first sign of rash and do not restart, and review emergent psychiatric symptoms and misuse risk. Do not use during pregnancy; ensure effective contraception during treatment and for two months after stopping, accounting for reduced effectiveness of steroidal contraceptives.
Contraindicated after myocardial infarction within the past year, in unstable angina, uncontrolled hypertension, serious cardiac arrhythmias or other serious heart disease, and with a monoamine oxidase inhibitor or within 14 days after it is stopped. Control hypertension before treatment, measure blood pressure and heart rate before and during treatment, and monitor psychiatric symptoms, interactions and misuse risk.